Large Cap BSE: 500087 NSE: CIPLA
19.4 (1.76%)
  • Advice
  • Hold
As on 29 November, 2022 | 20:16

Cipla Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in CIPLA

Start SIP

Cipla Share Price

Cipla Share Returns

  • Over 1 Month -2.95%
  • Over 3 Month 10.21%
  • Over 6 Month 16.02%
  • Over 1 Year 16.18%

Cipla Key Statistics

P/E Ratio 34.9
PEG Ratio 136.5
Market Cap Cr 90,485
Price to Book Ratio 4.3
EPS 36
Dividend 0.4
Relative Strength Index 51.72
Money Flow Index 34.03
MACD Signal -2.08
Average True Range 22.9

Cipla Investment Rating

  • Master Rating:
  • Cipla has an operating revenue of Rs. 21,942.92 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 16% is great, ROE of 12% is good. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 8% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 72 which is a FAIR score but needs to improve its earnings, a RS Rating of 58 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 94 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Cipla Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 3,7463,0702,8823,9553,8593,9483,173
Operating Expenses Qtr Cr 3,0902,3002,5592,9152,9522,8722,583
Operating Profit Qtr Cr 1,0618573881,0409831,145650
Depreciation Qtr Cr 176107117134139137137
Interest Qtr Cr 8266889
Tax Qtr Cr 265221105243252288140
Net Profit Qtr Cr 720759653731782792413

Cipla Technicals


Current Price
19.4 (1.76%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 1117.01
  • 50 Day
  • 1106.25
  • 100 Day
  • 1075.05
  • 200 Day
  • 1015.97
  • 20 Day
  • 1123.87
  • 50 Day
  • 1117.03
  • 100 Day
  • 1060.89
  • 200 Day
  • 1015.85

Cipla Resistance and Support

First Resistance 1109.8
Second Resistance 1117.85
Third Resistance 1125.7
RSI 51.72
MFI 34.03
MACD Single Line -2.08
MACD -4.66
First Resistance 1093.91
Second Resistance 1086.05
Third Resistance 1078

Cipla Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,939,344 84,788,120 43.72
Week 1,878,903 97,872,068 52.09
1 Month 1,736,548 88,372,937 50.89
6 Month 1,697,789 78,879,277 46.46

Cipla Result Highlights

Cipla Synopsis

NSE-Medical-Generic Drugs

Cipla is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 13091.79 Cr. and Equity Capital is Rs. 161.36 Cr. for the Year ended 31/03/2022. Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380.
Market Cap 90,562
Sales 14,210
Shares in Float 54.07
No of funds 904
Yield 0.45
Book Value 3.95
U/D Vol ratio 0.8
LTDebt / Equity
Alpha 0.05
Beta 0.34


Owner NameSep-22Jun-22Mar-22Dec-21
Promoters 33.61%33.61%33.63%
Mutual Funds 13.78%13.39%13.91%
Insurance Companies 5.84%3.69%3.76%
Foreign Portfolio Investors 27.69%27.64%26.64%
Financial Institutions/ Banks 0.09%0.04%0.04%
Individual Investors 14.82%15.41%15.54%
Others 4.17%6.22%6.48%

Cipla Management

Name Designation
Dr. Y K Hamied Chairman
Mr. M K Hamied Vice Chairman
Ms. Samina Hamied Executive Vice Chairman
Mr. Umang Vohra Managing Director & Global CEO
Mr. S Radhakrishnan Non Exe.Non Ind.Director
Mr. Ashok Sinha Independent Director
Mr. P R Ramesh Independent Director
Mr. Robert Stewart Independent Director
Dr. Peter Mugyenyi Independent Director
Mr. Adil Zainulbhai Independent Director
Ms. Punita Lal Independent Director
Dr. Mandar Vaidya Independent Director

Cipla Forecast

Price Estimates


Other Analyst Rating

Cipla Corporate Action

Date Purpose Remarks
2022-11-04 Quarterly Results
2022-07-29 Quarterly Results
2022-05-10 Audited Results & Dividend
2022-01-25 Quarterly Results
2021-10-26 Quarterly Results
Date Purpose Remarks
2022-08-10 FINAL Rs.5.00 per share(250%)Dividend

Cipla MF Shareholding

Name Amount(cr)
SBI Nifty 50 ETF 151468
SBI Equity Hybrid Fund Regular Payout Inc Dist cum Cap Wdrl 56730
HDFC Balanced Advantage Fund Growth 49709
ICICI Prudential Balanced Advantage Fund Growth 44002
UTI Nifty 50 Exchange Traded Fund 39494

About Company

Cipla Ltd. is a pharmaceutical company in India with a strong global presence. With operations in 80 countries and 47 manufacturing facilities, it sells 1500 products in the market. The largest market of Cipla Ltd. is India, followed by Africa and North America.

The product profile of Cipla Ltd. ranges from drugs in the respiratory, pediatric asthma, nebulisation, anti-retroviral, urology, cardiology, anti-infective, CNS, and several other illnesses and disorders. Cipla's business is divided into three units - Generics and Branded Generics, Specialty and Consumer Health. 

The Generics and Branded Generics unit contributes around 19% of the pharmaceutical revenues in India. The division has 4,000+ partners covering the entire country and is constantly seeking to expand the product portfolio.

The Specialty unit focuses on speciality medicines in respiratory, CNS and critical care. This unit's operations are run under Cipla Technologies LLC (CipTec) and have its headquarters in San Diego, California. 

The Consumer Health Segment focuses on simplifying healthcare and offering simple and over-the-counter solutions to the consumers. A few brands under this business unit are Nicotex, ActivKids ImmunoBoosters, Cofsils, and UnoBiotics.

History of Cipla Ltd.

Cipla was founded in 1935 in Mumbai as Chemical Industrial & Pharmaceutical Laboratories Ltd. by Khwaja Abdul Hamied. The name of the company was changed to Cipla in 1984. It received a major boost in 1985 when the US FDA approved its bulk drug facility. Cipla went on to launch the world's first oral iron chelator in 1995. 

The company acquired the South African company Cipla-Medproin in 2013 and entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa in 2019.

In September 2021, Cipla Ltd. subscribed to 5% equity shares (on a fully diluted basis) of Swasth Digital Health Foundation. It is a not-for-profit organisation focused on building digital healthcare infrastructure.

Shareholding Pattern

As of March 2022, the promoters at Cipla Ltd. hold 33.63% of the shares. FIIs hold 30.67%, and DIIs have 17.97% of their stocks. A total of 230 mutual funds invest in Cipla Ltd., with a total holding of 13.91%. The number of FIIs and FPIs that have invested in it is 786, and their total holding amount to 26.64. These figures are as of March 2022.

The top mutual funds that have invested in Cipla Ltd. are SBI ETF Nifty 50, Baroda BNP Paribas Balanced Advantage Fund Regular Growth, Mirae Asset Healthcare Fund Regular Growth, Franklin India Bluechip Fund-Growth and UTI Nifty ETF.

Cipla FAQs

What is Share Price of Cipla ?

Cipla share price is ₹1121 As on 29 November, 2022 | 20:02

What is the Market Cap of Cipla ?

The Market Cap of Cipla is ₹90485 Cr As on 29 November, 2022 | 20:02

What is the P/E ratio of Cipla ?

The P/E ratio of Cipla is 34.9 As on 29 November, 2022 | 20:02

What is the PB ratio of Cipla ?

The PB ratio of Cipla is 4.3 As on 29 November, 2022 | 20:02

Is it the right time to invest in Cipla?

Cipla may be the correct pick right now for investors searching for value buys of quality stocks with a longer time horizon. Cipla comes with a HOLD recommendation from the analyst. Cipla has a trailing 12-month operating revenue of INR 20,799.29 crore. Annual revenue growth of 11% is strong, the pre-tax margin of 17% is excellent, and ROE of 13% is excellent. The company has a debt-to-equity ratio of 7%, which indicates a stable balance sheet. Institutional holding has gone up in the last reported quarter is a positive sign.

Is Cipla an Indian company?

Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical corporation. Cipla primarily produces drugs for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical disorders.

Who is the CEO of Cipla?

Umang Vohra has been the CEO of Cipla since 1 September 2016.

What is Cipla's stock price CAGR?

Cipla's stock price CAGR over ten years is 11%, five years is 10%, three years is 20%, and one year is 22% percent.

How to buy Cipla Ltd. shares?

You can easily buy the shares of Grasim Industries Ltd. by registering at 5Paisa and setting up a Demat Account in your name to start trading.

What is the ROE of Cipla Ltd.?

The Return on Equity of the stock is 13.5% as of March 2022.